The Impact of a Post-Prescription Review and Feedback Antimicrobial Stewardship Program in Lebanon.
COVID-19
antimicrobial stewardship
disaster planning
global health
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
11 May 2022
11 May 2022
Historique:
received:
06
03
2022
revised:
05
05
2022
accepted:
09
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Antimicrobial stewardship programs (ASPs) are effective means to optimize prescribing practices. They are under-utilized in the Middle East where many challenges exist for ASP implementation. We assessed the effectiveness of infectious disease physician-driven post-prescription review and feedback as an ASP in Lebanon. This prospective cohort study was conducted over an 18-month period in the medical, surgical, and intensive care units of a tertiary care hospital. It consisted of three phases: the baseline, intervention, and follow-up. There was a washout period of two months between each phase. Patients aged ≥16 years receiving 48 h of antibiotics were included. During the intervention phase, the AMS team reviewed antimicrobial use within 72 h post-prescription and gave alternate recommendations based on the guidelines for use. The acceptance of the recommendations was measured at 72 h. The primary outcome of the study was days of therapy per 1000 study patient days. A total of 328 patients were recruited in the baseline phase (August−October 2020), 467 patients in the intervention phase (January−June 2021), and 301 patients in the post-intervention phase (September−December 2021). The total days of therapy decreased from 11.46 during the baseline phase to 8.64 during the intervention phase (p < 0.001). Intervention acceptance occurred 88.5% of the time. The infectious disease physician-driven implementation of an ASP was successful in reducing antibiotic utilization in an acute care setting in Lebanon.
Identifiants
pubmed: 35625286
pii: antibiotics11050642
doi: 10.3390/antibiotics11050642
pmc: PMC9138162
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antibiotics (Basel). 2021 Oct 29;10(11):
pubmed: 34827257
Curr Infect Dis Rep. 2020;22(9):23
pubmed: 32834785
Pharm Pract (Granada). 2021 Jan-Mar;19(1):2192
pubmed: 33727992
Antibiotics (Basel). 2020 Dec 16;9(12):
pubmed: 33339283
Lancet. 2019 Oct 12;394(10206):1311-1312
pubmed: 31609216
East Mediterr Health J. 2017 Aug 20;23(6):430-440
pubmed: 28836656
JAMA. 1996 Jan 17;275(3):234-40
pubmed: 8604178
Infect Dis Clin North Am. 2014 Jun;28(2):169-75
pubmed: 24857386
Infect Control Hosp Epidemiol. 2019 May;40(5):512-519
pubmed: 31084674
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399
pubmed: 32603803
Clin Infect Dis. 2017 Mar 1;64(5):537-543
pubmed: 27927861
FEMS Microbiol Ecol. 2021 Aug 17;97(9):
pubmed: 34329434
Infect Drug Resist. 2020 Dec 29;13:4713-4738
pubmed: 33402841
Am J Trop Med Hyg. 2019 Oct;101(4):923-928
pubmed: 31392949
Shock. 2020 Nov;54(5):644-651
pubmed: 32826818
World J Emerg Surg. 2018 Jun 28;13:27
pubmed: 29988647
J Antimicrob Chemother. 2017 Mar 1;72(3):933-940
pubmed: 27999034
J Infect Public Health. 2021 Jul;14(7):978-984
pubmed: 34130122
Int J Infect Dis. 2021 Apr;105:746-752
pubmed: 33737132
Antimicrob Resist Infect Control. 2014 Oct 23;3(1):33
pubmed: 25392736
J Glob Health. 2021 Mar 27;11:03052
pubmed: 33828836
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Saudi Pharm J. 2020 Oct;28(10):1166-1171
pubmed: 33132709
Infect Dis Rep. 2017 Oct 02;9(3):7268
pubmed: 29071048